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ABSTRACT
Aim: To report long term oncologic outcomes after adjuvant radiotherapy (RT) 
for stage I seminoma.
Method: We reviewed the complete data set for all patients treated at our 
institute between 1988 and 2005 for stage I seminoma with adjuvant RT after radical 
orchiectomy . 
Results: A total of 85 patients were included. The median follow-up was 15 years. 
The 20-year overall survival (OS) and relapse free survival (RFS) were 92% and 
96.3%, respectively. No severe acute and late complications were recorded. Overall 
5.9% of patients had a second unrelated malignancy.
Conclusion: Adjuvant RT is an efficacious and safe treatment in stage I seminoma.
INTRODUCTION
The vast majority of patients (70% to 80%) 
diagnosed with seminoma present stage I disease [1]. 
The primary treatment involves a surgical approach 
with radical inguinal orchiectomy. Although the cure rates 
exceed 95%, the optimal post-orchiectomy management 
remains still debated [1-2]. Radiation therapy (RT), 
chemotherapy (CHT) and surveillance have evolved 
separately but currently they are all considered acceptable 
options with quite similar overall survival (OS) outcome 
[2-3].
Over the years, RT has been the principal player 
alongside surgery, due to cells radiation sensitive 
characteristic. Postoperative RT had a well-documented 
history as adjuvant treatment of stage I seminoma with 
an overall relapse rate less than 5% at 5-10 years [4-
5]. Acute side effects are usually mild and predictable, 
whereas incidence of secondary malignancies is difficult 
to determine. 
A randomized trial has investigated single-dose 
carboplatin as an alternative to RT, and it has been 
suggested that single course of carboplatin is non-inferior 
to RT, with similar 5-year relapse rate, but its long effects 
are still hampered by a short follow-up period [6-7]. 
With active surveillance, adjuvant treatment is 
deferred at relapse. The relapse rate is 13% to 24% and 
salvage therapy is related to recurrence stage disease [8-9].
At our institute, stage I seminoma has for years 
been routinely treated with adjuvant RT. The purpose 
of this study is to report long-term follow-up data, in 
order to analyze related toxicity, incidence of secondary 
malignancies and oncologic outcomes. 
MATERIALS AND METHODS
Patients
We reviewed retrospectively the medical data of all 
consecutive patients treated for stage I seminoma between 
1988 and 2005 at our institute. The year 2005 was chosen 
to allow an adequate follow-up. The study was approved 
by the institutional review board and the scientific review 
committee. Data collected included demographics, initial 
stage disease, treatment details and follow-up.
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Staging system
The extent of primary disease was classified after 
radical orchiectomy, according to the American Joint 
Committee on Cancer tumor (T), nodes (N), metastasis 
(M) Staging System [2]. Stage I disease included pT1-
4 N0 M0 and normal serum tumor markers (if marker 
studies available or performed).
Treatment
All patients underwent radical inguinal orchiectomy, 
followed by adjuvant RT. If sperm banking was wished, it 
was performed either before surgery or RT.
RT was delivered using linear accelerator (4-15 
MV). All patients were treated supine, with knee support. 
Midline and lateral markers were used to align the patient 
and to prevent lateral rotation. Patients were planned 
conventionally in a simulator. 
Treatment field covered from T10-T11 superiorly to 
L5-S1 inferiorly. For dog-leg field, the inferior border lay 
in the top of obturator foramen to include ipsilateral iliac 
region and surgical scar. Prescribed dose was 30 Gy (2 Gy 
/ fraction) until October 2001, and 25.2 (1.8 Gy / fraction) 
thereafter.
Follow-up
Follow-up consisted in complete clinical 
examination and routine tests, including tumor markers 
alpha-fetoprotein (α-FP), human chorionic gonadotropin 
(β-hCG) and lactate dehydrogenase every three months for 
the first year, every four months for the second year, twice 
per year for the third year, annually until year ten, and 
every two years thereafter. Pelvic computed tomography 
(CT) was performed every 6-12 months for the first 3 
years and no routine CT were conducted thereafter.
Statistical analysis
Standard descriptive statistics were used to evaluate 
the distribution of each potential factor. Continuous 
variables were presented as medians and ranges, and 
dichotomous variables were presented as percentages. 
Data were compared using non-parametric Fisher 
exact test for qualitative data and the Wilcoxon test for 
quantitative data.
Overall survival (OS) and relapse free survival 
(RFS) were calculated in months from the date of the 
end of CRT to the first event, including date of the last 
follow-up or death (OS), and/or relapse (RFS). Second 
malignancy was defined as the diagnosis of a new 
tumor lesion detected at least 5 years after the end of 
RT. OS and RFS were estimated according to Kaplan-
Meier method. Statistical analysis was performed using 
RStudio-0.98.1091 software. 
RESULTS
Patient and treatment characteristics
Overall 85 patients were included in the study. 
Patients and tumor characteristics are shown in Table 
1. Preoperative serum tumor markers were recorded in 
74.1% of patients (n = 67) and levels were in the normal 
range before RT. Median age at diagnosis was 36 years 
(range 22 – 77). The vast majority of patients (n = 58; 
68.2%) had RT to abdominal and ipsilateral pelvic lymph 
nodes. Treatment details are given in Table 2.
Clinical outcomes
At the date of analysis, 4 patients (4.7 %) were dead, 
76 patients (89.4 %) were alive and 5 patients (5.9 %) 
were lost for follow-up. No patient had died of seminoma 
cancer. Major causes of death were related to a second 
carcinoma (n = 2) or to other coexisting medical condition 
(n = 2). The median follow-up was 15 years (range 7 – 
26).
The 10- and 20-year OS rates for the entire group 
of patients were 100% and 92% (95% CI: 0.79 - 0.97), 
respectively. The 10- and 20-year RFS were estimated at 
96.3% (95% CI 0.89 - 0.99) (Figure 1). All relapses (n 
= 3; 3.5%) occurred in those patients with pT2 disease 
and within 2 years after RT. Treatment was chemotherapy, 
based on bleomycin, etoposide and cisplatin (BEP) 
regimen in case of pelvic (iliac nodes, n = 2) and distant 
relapse (mediastinal mass, n = 1). Of the patients who 
relapsed, all are still alive and disease free.
Second malignancies
Overall 6 patients (7.1%) developed a second cancer 
and all of these patients were treated with “dog-leg” field. 
There have been 1 (1.2%) controlateral testicular tumor, 
and 5 (5.9%) unrelated tumors, including 1 leukemia and 
4 solid carcinomas (kidney, n = 1; lung, n =1; pancreas, n 
= 1, neurofibrosarcoma, n = 1). Median time to secondary 
malignancies was 18 years (range, 13-26) and most of 
them (n = 4; 66.7%) were observed beyond 15 years after 
the end of RT. 
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Acute and late toxicity
Details are shown in Table 3. Overall data on acute 
and late toxicity were not significantly different between 
RT treatment field. 
Among the 85 patients, there were no severe (> 
grade 2) acute complications. The main acute symptoms 
were nausea (n = 41; 48.2%), associated with vomiting 
in 3 cases only, and diarrhoea (n = 15; 17.6%). No 
hematologic or renal acute toxicity has been observed. 
Late treatment related toxicity included infertility (n 
= 7; 8.2%), cardiovascular disease (n = 1; 1.2%), poliposis 
of the gastrointestinal tract (n = 2; 2.4%) and peptic ulcer 
disease (n = 1; 1.2%). No osteonecrosis was recorded.
DISCUSSION AND CONCLUSIONS
Our results demonstrate an excellent prognosis in 
stage I seminoma patients after adjuvant RT. Over the 
time period of the study, RT treatment policies evolved 
to reflect the tendency toward lower doses and smaller 
volumes. However, the vast majority of patients reported 
a satisfactory quality of life (QoL), without severe 
complications, including cancer/treatment related death. 
Second cancer remains the major late treatment related 
morbidity, with a small risk (5.9%) of unrelated secondary 
malignant tumors.
These results are consistent with those reported 
in literature. In general it is assumed an actuarial risk of 
second malignancies from 5% to 8% [10]. The largest 
study of second cancers in testicular cancer survivors was 
presented by Travis et al [11]. Results showed a decreasing 
risk for second cancers with increasing age at diagnosis. 
Survivors were at statistically significant increased risk of 
solid tumors for at least 35 years after the end of RT and at 
20 years after RT the cancer risk was double over general 
population [11].
Surgery followed by RT has been known for decades 
to be the cornerstone of stage I seminoma treatment. In 
the recent years, adjuvant RT has been removed from 
most clinical guidelines principally due to the discover 
of the induced secondary cancers. Several alternatives to 
adjuvant RT have been proposed and current treatment 
options include active surveillance or adjuvant CHT in the 
form of carboplatin. 
Treatment-related effects are extremely important in 
stage I seminoma, due to its exceptionally high cure rate 
and its peak of young age diagnosis. Long term cancer 
survivors have a life expectancy of 40-60 years following 
to successful treatment. Late toxicities, especially second 
malignancies, are the most serious effect from seminoma 
RT treatment. But it should be noted that there are limited 
experience that analyse second malignancy risk in patients 
treated with alternatives to adjuvant RT.
Active surveillance strategy is based on regular 
follow-up, including markers, chest radiograph and 
abdominal/pelvic CT scan, to detect any recurrence 
at an early stage. Even if patients experience a certain 
level of anxiety due to fear of recurrence, surveillance 
management can avoid further treatment. Warde et al. 
identified two risk factors, including size of primary 
tumor and rete testis involvement, as significant prognostic 
factors for recurrence in stage I seminoma [12]. Despite 
the difficulties in discerning rete testis invasion, as well 
as in defining tumor size due to lesion multifocality, it 
has been possible to structure a prognostic nomogram 
model, using these two risk factors. Recurrence risk was 
estimated over 30% in case of both risk factors, whereas 
it was only half of that in case of only one or neither 
Table 1: Patients and tumor characteristics Table 2: Radiation therapy treatment details
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risk factor [13]. However, overall post resection relapse 
rate is approximately 20 % and patients who relapsed 
will receive more anticancer treatment than is needed in 
adjuvant setting [14]. 
Moreover, considering the young age of many 
patients and the non-specificity of tumor markers, 
surveillance strategy involves multiple serial abdominal/
pelvic CT over a long time period. For instance, the 
NCCN surveillance protocol recommends an abdominal/
pelvic CT at 3,6, and 12 months during the first 1 year 
Figure 1: Kaplan Meier curves of overall survival (OS) and relapse free survival (RFS)
Table 3: Incidence of acute and late toxicity
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of follow-up, every 6-12 months during the second and 
third year and annually thereafter [2]. Consequently the 
routinely use of CT scan exposes patients to low-level 
of ionising radiations that are associated at some risk of 
induced cancer. It has been estimated that the relative risk 
of a secondary malignancy with surveillance program 
compared to a single CT after surgery is approximately 
15.2 [15]. Anyway, definitive data on potential late effects, 
in term of second cancer risk related to surveillance 
strategy, as well as comparative data with RT long term 
toxicity are still lacking in literature and further studies 
are necessary. 
Adjuvant CHT represents another valid approach. 
Adjuvant carboplatin is the main option that has been 
explored over the years. The MRC TE19/EORTC trial 
was the first study that describes the use of carboplatin in 
adjuvant setting [6]. Patients were randomized either RT 
either carboplatin single cycle. Update results confirmed 
the non inferiority of CHT versus RT in term of RFS at 
5 years (94.7 % versus 96%, respectively) [7]. However 
the trial was originally powered to exclude a 3% absolute 
relapse difference in any pair-wise comparison (30 Gy 
versus 20 Gy versus carboplatin); RFR absolute difference 
at 5 years was estimated 1.34% (90% CI, - 0.7% to 3.5%), 
thus the primary outcome measure was not completely 
achieved.
However, independently of post-orchiectomy 
management, young adult patients continue to be treated, 
therefore it is important to evaluate future risks.. It is 
evident that effects on QoL have become one of the 
important factors influencing patients and clinicians in 
choosing the best therapy approach. Although an increased 
risk of second cancer is recognised after RT, its impact 
after CHT or surveillance remains controversial. Adjuvant 
RT might represent an overtreatment, but improved 
outcomes after CHT or surveillance are needed.
This study had several limitations. Our knowledge 
about late effects is based on treatment that was 
administered over 10 years ago and thus it implicated a 
retrospective nature of the study. However, this is the first 
long-term follow-up analysis showing oncologic outcomes 
at 20 years. Only few patients were lost at follow up 
and therefore results were not negatively affected, but a 
detailed assessment of fertility and gonadal status was not 
possible, due to missing data in a significant proportion 
of reports.
Cure rate is very high with either surveillance or 
adjuvant treatment following radical orchiectomy.
The potential of relapse using surveillance, on one 
hand, and the potential of late toxic effects especially from 
adjuvant treatment, on the other hand, should be carefully 
considered. It should be recommend patient autonomy, 
after unbiased information. Surely, a more precise risk 
classifications and a matured data on both adjuvant CHT 
and surveillance long-term toxicity could improve quality 
of clinical advise. 
Stage I seminoma patients have an excellent 
prognosis. Our results confirmed RT efficacy in this 
setting of patients. The minimal risk of relapse and the 
low incidence of late effects justify adjuvant RT. Waiting 
for surveillance and CHT mature long term toxicity 
data, a long-time horizon in decision-making should be 
recommended.
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